Medicine · Research · Innovation

Dr. Julian Borges, MD

Endocrinologist, physician-researcher, and data scientist. Over twenty years integrating endocrinology, clinical nutrition, genomic medicine, precision medicine, and AI in healthcare.

SBEM RQE 9620 ABRAN RQE 9074 Harvard GCSRT BU MS Health Informatics
20+
Years of practice
68+
Peer-reviewed publications
3
Editorial positions
6
Scientific societies
14
Academic programs
I · II · III

Three domains of practice

I

Clinical Practice

Endocrinology, diabetes, and metabolism with integrated clinical nutrition assessment. Management of thyroid, adrenal, pituitary, gonadal, and metabolic disorders, including evidence-based hormone replacement therapy.

View practice →
II

Academic Research

68+ peer-reviewed publications in translational cardiology, genomic medicine, hormone replacement therapy, metabolic disease, endocrine genetics, and cardiometabolic biomarkers. Book published on functional foods.

View publications →
III

Medical Education

Associate Professor of Medicine at Afya Medical Post Graduation Institute. Editor for three international academic publishers, including Editor-in-Chief at Aditum Publishing LLC.

View editorial positions →
IV

Featured publication

Book · 2025

Functional Foods and Nutraceuticals: Definitions and Health Benefits

A 2025 book consolidating current evidence on functional foods and nutraceuticals, their mechanisms of action, and clinical applications in metabolic, cardiovascular, and endocrine disorders.

ISBN 978-65-98382-62-9 DOI 10.54448/MSP Clinical nutrology
IV.

Research program

Active research lines

Program in pre-seed research and development phase. Continuous output of peer-reviewed publications indexed on ORCID, with nine endocrine domains under translational investigation.

Cardiometabolic risk and diabetes

Machine learning applied to risk stratification in diabetic populations. Two peer-reviewed articles in 2025 and 2026 exploring deep learning for cardiac disease and predictive models for metabolic complications. Integration of classical biomarkers with genomic profiles for personalized intervention.

Hypothalamic-pituitary-gonadal axis

Research in male hypogonadism, iron overload as modulator of the HPG axis, oral testosterone therapy in systematic meta-analysis, and erectile dysfunction as cardiometabolic biomarker. Three peer-reviewed publications between 2024 and 2026 document the line.

Mitochondrial health and bioenergetics

Role of coenzyme Q10 in cardiovascular disease with translational meta-analysis. Mitochondrial dysfunction in endocrine conditions. Integrated evaluation of energy cofactors (CoQ10, carnitine, NAD+) in the context of chronic fatigue and metabolic dysregulation.

Neuroendocrinology and neurodegeneration

HFE polymorphisms and CYP19A1 variants in neurodegeneration and neurodevelopment. Recent systematic review on HFE genotype and neurodegenerative diseases. Line aligned with genomic medicine applied to brain aging.

V.

Editorial leadership

Editorial roles in peer-reviewed journals

Editor-in-Chief of an international scientific journal. Academic Editor at PLOS and Science Publishing Group. Editorial leadership as central activity of the research practice.

2025 - present

Editor-in-Chief

International Journal of Epidemiology and Public Health Research

Editorial leadership position in international peer-reviewed journal. Responsible for scientific direction, methodological quality validation, and peer reviewer coordination.

2024 - present

Editor-in-Chief

Aditum Publishing LLC

Editorial role across Aditum publisher journals. Manuscript evaluation in endocrinology, metabolism, precision medicine, and clinical AI governance.

2025 - present

Academic Editor

PLOS

Academic evaluation of manuscripts submitted to PLOS. Position reserved for researchers with recognized productivity in specific area of editorial focus.

2024 - present

Academic Editor

Science Publishing Group

Academic editor role across Science Publishing Group journals. Coordination of peer review process for manuscripts in endocrine and metabolic areas.

VI.

Intellectual property

USPTO record

Three provisional patents filed at the United States Patent and Trademark Office between February and March 2026. Two USPTO trademarks in Class 042. All contributions grounded in governance as a viability constraint, not post hoc oversight.

Patent 01 - Foundation

Externally Governed Learning Systems

US Provisional 63/975,551. Foundational architecture for adaptive artificial intelligence systems in medicine. Origin in Harvard Medical School GCSRT thesis.

Patent 02 - Engine

MedBoard AI Adaptive Engine

US Provisional 64/012,574. Three-tier Analyst, Strategist, Judge architecture with EGLS governance. Twenty-seven claim follow-on specification.

Patent 03 - Pipeline

DrugSynthAI Discovery

US Provisional 64/018,624. Multi-agent pipeline for de novo molecule design targeting genetic disease. Three amendments filed.

Trademark 01 - Education

MedBoardPRO

USPTO Class 042. Serial 99721498. Trademark for adaptive medical licensure preparation platform. Section 1(b) Intent to Use.

Trademark 02 - Discovery

DrugSynthAI

USPTO Class 042. Trademark for governance-first drug discovery platform. Section 1(b) Intent to Use.

Current phase

Pre-seed, R&D

Focus on intellectual property generation, peer-reviewed publication output, and platform prototyping under unified governance framework. No commercial launch to date.